JP5154732B2 - 薬剤 - Google Patents
薬剤 Download PDFInfo
- Publication number
- JP5154732B2 JP5154732B2 JP2002562324A JP2002562324A JP5154732B2 JP 5154732 B2 JP5154732 B2 JP 5154732B2 JP 2002562324 A JP2002562324 A JP 2002562324A JP 2002562324 A JP2002562324 A JP 2002562324A JP 5154732 B2 JP5154732 B2 JP 5154732B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- bimodal
- composition according
- active ingredient
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title description 10
- 229940079593 drug Drugs 0.000 title description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 44
- 239000004480 active ingredient Substances 0.000 claims abstract description 30
- 230000002902 bimodal effect Effects 0.000 claims abstract description 21
- 210000004072 lung Anatomy 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 41
- 239000002245 particle Substances 0.000 claims description 29
- 239000003246 corticosteroid Substances 0.000 claims description 11
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 9
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 9
- 239000003380 propellant Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000000443 aerosol Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 229940112141 dry powder inhaler Drugs 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 241000206607 Porphyra umbilicalis Species 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 12
- 238000011260 co-administration Methods 0.000 abstract description 2
- 229940124630 bronchodilator Drugs 0.000 description 20
- 238000009472 formulation Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- -1 formoterol fumarate anhydride Chemical class 0.000 description 8
- 229960002848 formoterol Drugs 0.000 description 7
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 229960004017 salmeterol Drugs 0.000 description 6
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000000168 bronchodilator agent Substances 0.000 description 5
- 229960004436 budesonide Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229960002714 fluticasone Drugs 0.000 description 5
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 5
- 208000023504 respiratory system disease Diseases 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 4
- 229950000210 beclometasone dipropionate Drugs 0.000 description 4
- 229960000676 flunisolide Drugs 0.000 description 4
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 239000011362 coarse particle Substances 0.000 description 3
- 238000002664 inhalation therapy Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 229960003556 aminophylline Drugs 0.000 description 2
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229960003728 ciclesonide Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 229960001022 fenoterol Drugs 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
- 229960000193 formoterol fumarate Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960001361 ipratropium bromide Drugs 0.000 description 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229940066491 mucolytics Drugs 0.000 description 2
- RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 2
- 229960002720 reproterol Drugs 0.000 description 2
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229960000195 terbutaline Drugs 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- BOSAWIQFTJIYIS-UHFFFAOYSA-N 1,1,1-trichloro-2,2,2-trifluoroethane Chemical compound FC(F)(F)C(Cl)(Cl)Cl BOSAWIQFTJIYIS-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- RFCAUADVODFSLZ-UHFFFAOYSA-N 1-Chloro-1,1,2,2,2-pentafluoroethane Chemical compound FC(F)(F)C(F)(F)Cl RFCAUADVODFSLZ-UHFFFAOYSA-N 0.000 description 1
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
- HQARDVLSJLCFBA-UHFFFAOYSA-N 4-[(4-aminophenyl)carbamoyl]-1h-imidazole-5-carboxylic acid Chemical compound C1=CC(N)=CC=C1NC(=O)C1=C(C(O)=O)NC=N1 HQARDVLSJLCFBA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000004340 Chloropentafluoroethane Substances 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000013521 Visual disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 235000019406 chloropentafluoroethane Nutrition 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical compound CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229960002259 nedocromil sodium Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0102902.4A GB0102902D0 (en) | 2001-02-06 | 2001-02-06 | Medicaments |
| GB0102902.4 | 2001-02-06 | ||
| GB0109215A GB0109215D0 (en) | 2001-04-12 | 2001-04-12 | Medicaments |
| GB0109215.4 | 2001-04-12 | ||
| PCT/GB2002/000480 WO2002062317A2 (en) | 2001-02-06 | 2002-02-05 | Bimodal dry powder formulation for inhalation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004523536A JP2004523536A (ja) | 2004-08-05 |
| JP2004523536A5 JP2004523536A5 (enExample) | 2005-12-22 |
| JP5154732B2 true JP5154732B2 (ja) | 2013-02-27 |
Family
ID=26245685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002562324A Expired - Fee Related JP5154732B2 (ja) | 2001-02-06 | 2002-02-05 | 薬剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20060292085A1 (enExample) |
| EP (1) | EP1359902B1 (enExample) |
| JP (1) | JP5154732B2 (enExample) |
| AT (1) | ATE369121T1 (enExample) |
| BR (1) | BR0207062A (enExample) |
| CA (1) | CA2435982C (enExample) |
| DE (1) | DE60221640T2 (enExample) |
| ES (1) | ES2291452T3 (enExample) |
| MX (1) | MXPA03007017A (enExample) |
| NO (1) | NO20033451L (enExample) |
| PL (1) | PL365736A1 (enExample) |
| WO (1) | WO2002062317A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6962151B1 (en) * | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| AU2003293833B2 (en) | 2002-12-12 | 2009-10-01 | Covis Pharma B.V. | Combination medicament |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| MX2015013845A (es) | 2013-04-01 | 2016-05-09 | Pulmatrix Inc | Polvos secos de tiotropio. |
| CA2965759C (en) | 2014-10-31 | 2023-12-12 | Glaxosmithkline Intellectual Property Development Limited | Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US385626A (en) * | 1888-07-03 | Farm-gate | ||
| US5A (en) * | 1836-08-10 | Thomas Blanchard | Machine for mortising solid wooden shells of ships' tackle-blocks | |
| US1858735A (en) * | 1930-07-03 | 1932-05-17 | Elwin M Goodsell | Dispenser for tobacco or granular material |
| US2587215A (en) * | 1949-04-27 | 1952-02-26 | Frank P Priestly | Inhalator |
| LU53824A1 (enExample) * | 1967-06-06 | 1969-03-24 | ||
| JPS4837815B1 (enExample) * | 1970-09-25 | 1973-11-14 | Yamanouchi Pharma Co Ltd | |
| GB1410588A (en) * | 1971-08-10 | 1975-10-22 | Fisons Ltd | Composition |
| US3876269A (en) * | 1973-04-23 | 1975-04-08 | James N Fisher | Preprogrammed medication dispenser |
| US3874381A (en) * | 1974-05-28 | 1975-04-01 | Smithkline Corp | Dual nozzle intranasal delivery device |
| US4047635A (en) * | 1975-08-28 | 1977-09-13 | Bennett Jr Arthur A | Article dispensing apparatus for selectively dispensing articles |
| SE408265B (sv) * | 1975-12-12 | 1979-06-05 | Draco Ab | Anordning for koldioxiddriven endosaerosol, avsedd for inhalering |
| DE2716323C2 (de) * | 1977-04-07 | 1986-03-13 | Schering AG, 1000 Berlin und 4709 Bergkamen | Vorrichtung zur Inhalation von Arzneimitteln |
| US4274403A (en) * | 1979-08-29 | 1981-06-23 | Struve Roger L | Inhaler |
| ES8206980A1 (es) * | 1980-10-30 | 1982-09-01 | Riker Laboratories Inc | Un dispositivo para facilitar la inhalacion oral de medica- mentos en forma de polvo |
| DE3274065D1 (de) * | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
| US4570630A (en) * | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
| US4604847A (en) * | 1983-09-14 | 1986-08-12 | Moulding Jr Thomas S | Medicine package, method of opening the package, and machine for performing the method |
| US4534343A (en) * | 1984-01-27 | 1985-08-13 | Trutek Research, Inc. | Metered dose inhaler |
| SE448277B (sv) * | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| AU587472B2 (en) * | 1985-05-22 | 1989-08-17 | Liposome Technology, Inc. | Liposome inhalation method and system |
| US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
| US4635829A (en) * | 1985-05-30 | 1987-01-13 | Brittingham Jr Louis W | Measured volume dispenser |
| FR2584604B1 (fr) * | 1985-07-15 | 1988-11-04 | Veyron Froment Laboratoire | Composition therapeutique constituant une nouvelle forme galenique orale pour ameliorer la cinetique de la biodisponibilite |
| GB2178965B (en) * | 1985-07-30 | 1988-08-03 | Glaxo Group Ltd | Devices for administering medicaments to patients |
| SE453566B (sv) * | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
| SE8601351D0 (sv) * | 1986-03-24 | 1986-03-24 | Nilsson Sven Erik | Styrd administration av fysiologiskt aktiva emnen |
| US4950365A (en) * | 1988-12-22 | 1990-08-21 | Vac-Tec Systems, Inc. | Corrosion free hard coated metal substrates |
| US5208226A (en) * | 1989-09-08 | 1993-05-04 | Glaxo Group Limited | Medicaments |
| US5007419A (en) * | 1989-09-25 | 1991-04-16 | Allan Weinstein | Inhaler device |
| US5002048A (en) * | 1989-12-12 | 1991-03-26 | Makiej Jr Walter J | Inhalation device utilizing two or more aerosol containers |
| US5113855A (en) * | 1990-02-14 | 1992-05-19 | Newhouse Michael T | Powder inhaler |
| GB9015522D0 (en) * | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
| IT1243344B (it) * | 1990-07-16 | 1994-06-10 | Promo Pack Sa | Inalatore plurimonodose per medicamenti in polvere |
| DE4027390C2 (de) * | 1990-08-30 | 1994-11-03 | Boehringer Ingelheim Kg | Treibgasfreies Inhalationsgerät |
| DE4027391A1 (de) * | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | Treibgasfreies inhalationsgeraet |
| FR2667509B1 (fr) * | 1990-10-04 | 1995-08-25 | Valois | Inhalateur a poudre, dispositif de conditionnement de microdoses de poudre sous forme de bandes adaptees a etre utilisees dans un inhalateur a poudre, et procede de fabrication de ces bandes. |
| US5042472A (en) * | 1990-10-15 | 1991-08-27 | Merck & Co., Inc. | Powder inhaler device |
| GB9027234D0 (en) * | 1990-12-15 | 1991-02-06 | Harris Pharma Ltd | An inhalation device |
| US5404871A (en) * | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
| AU6130394A (en) * | 1991-03-05 | 1994-08-15 | Miris Medical Corporation | Apparatus for providing a timed release of an amount of aerosol medication |
| ES2093702T3 (es) * | 1991-04-15 | 1997-01-01 | Leiras Oy | Dispositivo para medir una dosis de medicamento en polvo para inhalacion. |
| DE4211475A1 (de) * | 1991-12-14 | 1993-06-17 | Asta Medica Ag | Pulverinhalator |
| GB9203761D0 (en) * | 1992-02-21 | 1992-04-08 | Innovata Biomed Ltd | Inhaler |
| CA2115065C (en) * | 1992-06-12 | 2000-10-03 | Kiyoyuki Sakon | Ultrafine particle powder for inhalation and method for production thereof |
| US5394868A (en) * | 1992-06-25 | 1995-03-07 | Schering Corporation | Inhalation device for powdered medicaments |
| TW223015B (enExample) * | 1992-07-01 | 1994-05-01 | Duphar Int Res | |
| US5785049A (en) * | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| DE4239402A1 (de) * | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
| RU2111020C1 (ru) * | 1992-12-18 | 1998-05-20 | Шеринг Корпорейшн | Ингалятор для порошковых лекарств |
| US5896855A (en) * | 1992-12-24 | 1999-04-27 | Rhone-Poulenc Rorer Limited | Multi dose inhaler apparatus |
| US5411175A (en) * | 1993-03-08 | 1995-05-02 | New England Pharmaceuticals, Inc. | Cartridges, devices and methods for dispensing liquids |
| GB9312984D0 (en) * | 1993-06-23 | 1993-08-04 | Bespak Plc | Atomising dispenser |
| IS1796B (is) * | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
| US5437267A (en) * | 1993-08-03 | 1995-08-01 | Weinstein; Allan | Device for delivering aerosol to the nasal membranes and method of use |
| US5524613A (en) * | 1993-08-25 | 1996-06-11 | Habley Medical Technology Corporation | Controlled multi-pharmaceutical inhaler |
| US5450160A (en) * | 1993-12-22 | 1995-09-12 | Eastman Kodak Company | Film cartridge magazine |
| US5415162A (en) * | 1994-01-18 | 1995-05-16 | Glaxo Inc. | Multi-dose dry powder inhalation device |
| US5664557A (en) * | 1994-03-10 | 1997-09-09 | Respiratory Delivery Systems, Inc. | Releasably engageable coupling for an inhaler |
| FI942196L (fi) * | 1994-05-11 | 1995-11-12 | Orion Yhtymae Oy | Jauheinhalaattori |
| US5775536A (en) * | 1994-07-29 | 1998-07-07 | Ortho Pharmaceutical Corp. | Variable day start tablet dispenser |
| US5562231A (en) * | 1994-07-29 | 1996-10-08 | Ortho Pharmaceutical Corporation | Variable day start tablet dispenser |
| DE69529104T2 (de) * | 1994-09-16 | 2003-07-17 | Laboratoire Glaxosmithkline S.A.S., Marly-Le-Roi | Inhalator |
| EP0705928B1 (de) * | 1994-10-07 | 1999-08-11 | Sulzer RàTi Ag | Wagen zum Wechseln des Webgeschirrs einer Webmaschine |
| US5485939A (en) * | 1994-11-09 | 1996-01-23 | Tucker; Gary D. | Lollipop dispenser apparatus |
| SE9404140D0 (sv) * | 1994-11-29 | 1994-11-29 | Astra Ab | Dose indicating device |
| GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
| US5921237A (en) * | 1995-04-24 | 1999-07-13 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
| US5622166A (en) * | 1995-04-24 | 1997-04-22 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
| AU128811S (en) * | 1995-06-06 | 1996-12-03 | Orion Yhtymae Oy | A protective cover for example a moisture protective cover for a powder inhaler |
| SE504458C2 (sv) * | 1995-06-21 | 1997-02-17 | Lars Gunnar Nilsson | Inhalator för elektrisk dosering av substanser |
| DE19523516C1 (de) * | 1995-06-30 | 1996-10-31 | Asta Medica Ag | Inhalator zum Verabreichen von Medikamenten aus Blisterpackungen |
| US5664697B1 (en) * | 1995-10-31 | 1998-09-15 | Ortho Pharma Corp | Automatically advancing pill regimen device |
| ATE209053T1 (de) * | 1996-01-03 | 2001-12-15 | Glaxo Group Ltd | Inhaliervorrichtung |
| ES2172763T3 (es) * | 1996-02-21 | 2002-10-01 | Schering Corp | Inhalador de medicamento en polvo. |
| US5875776A (en) * | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
| US6254854B1 (en) * | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| JPH09331451A (ja) * | 1996-06-11 | 1997-12-22 | Mita Ind Co Ltd | 画像読取装置 |
| GB9626233D0 (en) * | 1996-12-18 | 1997-02-05 | Chawla Brinda P S | Medicament packaging and deliveery device |
| GB9626263D0 (en) * | 1996-12-18 | 1997-02-05 | Innovata Biomed Ltd | Powder inhaler |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| SE9700424D0 (sv) * | 1997-02-07 | 1997-02-07 | Astra Ab | Powder inhaler |
| US6006747A (en) * | 1997-03-20 | 1999-12-28 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
| US5904139A (en) * | 1997-03-28 | 1999-05-18 | Hauser; Stephen G. | Breath coordinated inhaler |
| US5941241A (en) * | 1997-05-12 | 1999-08-24 | Weinstein; Robert E. | Method and device for organizing and coordinating the combined use of topical aerosols for the treatment of respiratory disorders |
| US5944660A (en) * | 1997-07-08 | 1999-08-31 | Optical Sensors Incorporated | Disposable cartridge assembly with optional integrated temperature control system, and systems containing same |
| CA2212430A1 (en) * | 1997-08-07 | 1999-02-07 | George Volgyesi | Inhalation device |
| SE9703407D0 (sv) * | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| US20010006939A1 (en) * | 1997-10-03 | 2001-07-05 | Ralph W. Niven | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
| GB9722285D0 (en) * | 1997-10-23 | 1997-12-17 | Rhone Poulenc Rorer Ltd | Inhalation device |
| US6116238A (en) * | 1997-12-02 | 2000-09-12 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
| ATE251482T1 (de) * | 1998-01-03 | 2003-10-15 | Innovata Biomed Ltd | Füllungsverfahren |
| DE19803524A1 (de) * | 1998-01-30 | 1999-08-05 | Grohe Armaturen Friedrich | Betätigungseinrichtung für ein Wasserventil |
| GB9807232D0 (en) * | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
| US6234167B1 (en) * | 1998-10-14 | 2001-05-22 | Chrysalis Technologies, Incorporated | Aerosol generator and methods of making and using an aerosol generator |
| GB9827200D0 (en) * | 1998-12-11 | 1999-02-03 | Glaxo Group Ltd | Dry powder inhaler |
| GB9903759D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| US6196218B1 (en) * | 1999-02-24 | 2001-03-06 | Ponwell Enterprises Ltd | Piezo inhaler |
| US6601729B1 (en) * | 1999-03-26 | 2003-08-05 | Papp Enterprises, Llc | Automated portable medication radial dispensing apparatus and method using a carrier tape |
| US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| GB9928265D0 (en) * | 1999-12-01 | 2000-01-26 | Innovata Biomed Ltd | Inhaler |
| CA2393428A1 (en) * | 1999-12-07 | 2001-06-14 | Kari Seppala | Multidose powder inhaler |
| GB0016478D0 (en) * | 2000-07-05 | 2000-08-23 | Innovata Biomed Ltd | Valve |
| US6543443B1 (en) * | 2000-07-12 | 2003-04-08 | Aerogen, Inc. | Methods and devices for nebulizing fluids |
| GB0102902D0 (en) * | 2001-02-06 | 2001-03-21 | Innovata Biomed Ltd | Medicaments |
| US6523536B2 (en) * | 2001-03-12 | 2003-02-25 | Birdsong Medical Devices, Inc. | Dual-canister inhaler having a spacer and easy to operate lever mechanism |
| US7931022B2 (en) * | 2001-10-19 | 2011-04-26 | Respirks, Inc. | Method and apparatus for dispensing inhalator medicament |
| GB0128148D0 (en) * | 2001-11-23 | 2002-01-16 | Innovata Biomed Ltd | Assembly |
| US20040101782A1 (en) * | 2002-11-27 | 2004-05-27 | General Electric Company | Method for making optical device structures |
-
2002
- 2002-02-05 JP JP2002562324A patent/JP5154732B2/ja not_active Expired - Fee Related
- 2002-02-05 EP EP02712031A patent/EP1359902B1/en not_active Revoked
- 2002-02-05 AT AT02712031T patent/ATE369121T1/de active
- 2002-02-05 WO PCT/GB2002/000480 patent/WO2002062317A2/en not_active Ceased
- 2002-02-05 ES ES02712031T patent/ES2291452T3/es not_active Expired - Lifetime
- 2002-02-05 MX MXPA03007017A patent/MXPA03007017A/es unknown
- 2002-02-05 DE DE60221640T patent/DE60221640T2/de not_active Expired - Lifetime
- 2002-02-05 PL PL02365736A patent/PL365736A1/xx unknown
- 2002-02-05 CA CA2435982A patent/CA2435982C/en not_active Expired - Fee Related
- 2002-02-05 BR BR0207062-6A patent/BR0207062A/pt not_active Application Discontinuation
-
2003
- 2003-08-04 NO NO20033451A patent/NO20033451L/no not_active Application Discontinuation
-
2006
- 2006-08-29 US US11/511,730 patent/US20060292085A1/en not_active Abandoned
-
2010
- 2010-01-07 US US12/683,959 patent/US20100136121A1/en not_active Abandoned
-
2014
- 2014-07-31 US US14/448,493 patent/US20140342001A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20033451D0 (no) | 2003-08-04 |
| US20060292085A1 (en) | 2006-12-28 |
| CA2435982C (en) | 2014-05-06 |
| NO20033451L (no) | 2003-10-03 |
| ES2291452T3 (es) | 2008-03-01 |
| US20100136121A1 (en) | 2010-06-03 |
| WO2002062317A2 (en) | 2002-08-15 |
| US20140342001A1 (en) | 2014-11-20 |
| ATE369121T1 (de) | 2007-08-15 |
| EP1359902B1 (en) | 2007-08-08 |
| WO2002062317A3 (en) | 2002-11-21 |
| PL365736A1 (en) | 2005-01-10 |
| DE60221640T2 (de) | 2008-05-21 |
| BR0207062A (pt) | 2004-10-05 |
| CA2435982A1 (en) | 2002-08-15 |
| JP2004523536A (ja) | 2004-08-05 |
| DE60221640D1 (de) | 2007-09-20 |
| EP1359902A2 (en) | 2003-11-12 |
| MXPA03007017A (es) | 2004-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8962601B2 (en) | Pharmaceutical products and composition comprising specific anticholinergic agents, β-2 agonists and corticosteroids | |
| AU2010215490B2 (en) | Pharmaceutical composition for inhalation | |
| JP2002537249A (ja) | 喘息のためのホルモテロールおよびプロピオン酸フルチカゾンの組み合わせ | |
| JP2000502365A (ja) | 新規な組み合わせ | |
| US20150283151A1 (en) | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same | |
| JP2004500429A (ja) | チオトロピウム及びロフレポニドを含む医薬用の組み合わせ | |
| JP2010539182A (ja) | 治療剤の新規組み合わせ | |
| CN102186458A (zh) | 治疗慢性阻塞性肺病及其它肺疾病的方法 | |
| US20140342001A1 (en) | Medicaments | |
| JP2009515941A (ja) | 医薬組成物 | |
| US20040101482A1 (en) | Medicaments | |
| CA2948553A1 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd | |
| WO2000053187A1 (en) | New combination of formoterol and mometasone in a pharmaceutical composition for treating respiratory disorders, such as asthma, rhinitis and copd | |
| KR101475262B1 (ko) | 천식 치료에 사용되는 흡입용 복합 조성물 | |
| HUP0303755A2 (hu) | Szalmeterol és flutikaszon-propionát kombináció alkalmazása és ezt tartalmazó gyógyszerkészítmény | |
| US20090246281A1 (en) | Soft steroid compositions for use in dry powder inhalers | |
| CN105338967A (zh) | 包含布地奈德和福莫特罗的药物组合物 | |
| Donnell | Inhaled corticosteroid delivery systems: clinical role of a breath-actuated device | |
| CN115989032A (zh) | 用于吸入施用的组合疗法 | |
| CA2456721C (en) | Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders | |
| AU2002231939A1 (en) | Bimodal dry powder formulation for inhalation | |
| HK40064779A (en) | Novel carrier particles for dry powder formulations for inhalation | |
| HK1232788A1 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd | |
| MXPA00009981A (en) | Use of a glucocorticosteroid for the manufacture of a medicament for treating mild/early forms of copd (chronic obstructive pulmonary disease) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050405 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081031 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090130 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090430 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090825 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120709 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120712 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120809 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120814 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120910 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120914 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121010 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121206 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151214 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5154732 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |